Amongst cancer patients, bone pain due to skeletal metastases is a major cause of
morbidity. A number of beta-emitting radiopharmaceuticals have been used to provide …

The aim of this paper is to investigate the feasibility and limitations of activity-concentration
estimation for 223 Ra using SPECT. Phantom measurements are performed using spheres …

Background We designed and synthesized a novel bisphosphonate radiopharmaceutical
(68 Ga-or 177Lu-labeled DOTA-ibandronate [68 Ga/177Lu-DOTA-IBA]) for the targeted …

Progression to androgen-independent status is the main cause of death in patients with
metastatic prostate cancer. Prostate-specific membrane antigen (PSMA) is anchored in the …

A newer therapy for the treatment of bone metastases due to castration-resistant prostate
cancer (mCRPC) is the administration of 223 Ra-dichloride (223 RaCl 2) or 177 Lu-iPSMA …

Objective: Dose optimization and pharmacokinetic evaluation of α-particle emitting radium-
223 dichloride (223RaCl2) by planar γ-camera or single photon emission computed …

Simple Summary Currently, patient-specific treatment plans and dosimetry calculations are
not routinely performed for radionuclide therapies. In external beam radiotherapy, it is quite …

Nuclear Medicine therapy has reached a critical juncture with an unprecedented number of
patients being treated and an extensive list of new radiopharmaceuticals under …

Introduction Radium-223 is an approved survival-prolonging treatment option in men with
castration-resistant prostate cancer (mCRPC) and bone metastases. In the registration trial …

Radiotheranostics utilizes a set of radioligands incorporating diagnostic or therapeutic
radionuclides to achieve both diagnosis and therapy. Imaging probes using diagnostic …